<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407950</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Impact and Effectiveness of COVID-19 Vaccines Based on Machine Learning Analysis of a Time Series: A Population-Based Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195890</ELocationID><Abstract><AbstractText><b>Background</b>: Although confirmed cases of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been declining since late 2020 due to general vaccination, little research has been performed regarding the impact of vaccines against SARS-CoV-2 in Spain in terms of hospitalizations and deaths. <b>Objective</b>: Our aim was to identify the reduction in severity and mortality of coronavirus disease 2019 (COVID-19) at a nationwide level due to vaccination. <b>Methods</b>: We designed a retrospective, population-based study to define waves of infection and to describe the characteristics of the hospitalized population. We also studied the rollout of vaccination and its relationship with the decline in hospitalizations and deaths. Finally, we developed two mathematical models to estimate non-vaccination scenarios using machine learning modeling (with the ElasticNet and RandomForest algorithms). The vaccination and non-vaccination scenarios were eventually compared to estimate the number of averted hospitalizations and deaths. <b>Results</b>: In total, 498,789 patients were included, with a global mortality of 14.3%. We identified six waves or epidemic outbreaks during the observed period. We established a strong relationship between the beginning of vaccination and the decline in both hospitalizations and deaths due to COVID-19 in all age groups. We also estimated that vaccination prevented 170,959 hospitalizations (CI 95% 77,844-264,075) and 24,546 deaths (CI 95% 2548-46,543) in Spain between March 2021 and December 2021. We estimated a global reduction of 9.19% in total deaths during the first year of COVID-19 vaccination. <b>Conclusions</b>: Demographic and clinical profiles changed over the first months of the pandemic. In Spain, patients over 80 years old and other age groups obtained clinical benefit from early vaccination. The severity of COVID-19, in terms of hospitalizations and deaths, decreased due to vaccination. Our use of machine learning models provided a detailed estimation of the averted burden of the pandemic, demonstrating the effectiveness of vaccination at a population-wide level.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Carretero</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7532-4585</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ordoñez-Garcia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez-Gomez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-6234-0188</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Maya</LastName><ForeName>Belen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Prieto</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5229-3832</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Rey Juan Carlos University, 28933 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-de-Miguel</LastName><ForeName>Angel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1295-7101</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Rey Juan Carlos University, 28933 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hospitalizations</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407950</ArticleId><ArticleId IdType="pmc">PMC11478103</ArticleId><ArticleId IdType="doi">10.3390/jcm13195890</ArticleId><ArticleId IdType="pii">jcm13195890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hosseinzadeh P., Zareipour M., Baljani E., Moradali M. Social Consequences of the COVID-19 Pandemic. A Systematic Review. Investig. Educ. Enferm. 2022;40:e10. doi: 10.17533/udea.iee.v40n1e10.</Citation><ArticleIdList><ArticleId IdType="doi">10.17533/udea.iee.v40n1e10</ArticleId><ArticleId IdType="pmc">PMC9052715</ArticleId><ArticleId IdType="pubmed">35485623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mofijur M., Rizwanul Fattah I.M., Alam M.A., Islam A.B.M.S., Ong H.C., Rahman S.M.A., Najafi G., Ahmed S.F., Uddin M.A., Mahlia T.M.I. Impact of COVID-19 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic. Sustain. Prod. Consum. 2021;26:343–359. doi: 10.1016/j.spc.2020.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spc.2020.10.016</ArticleId><ArticleId IdType="pmc">PMC7556229</ArticleId><ArticleId IdType="pubmed">33072833</ArticleId></ArticleIdList></Reference><Reference><Citation>Osofsky J., Osofsky H., Mamon L. Psychological and social impact of COVID-19. Psychol. Trauma Theory Res. Pract. Policy. 2020;12:468–469. doi: 10.1037/tra0000656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/tra0000656</ArticleId><ArticleId IdType="pubmed">32538653</ArticleId></ArticleIdList></Reference><Reference><Citation>Saladino V., Algeri D., Auriemma V. The Psychological and Social Impact of COVID-19: New Perspectives of Well-Being. Front. Psychol. 2020;11:577684. doi: 10.3389/fpsyg.2020.577684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.577684</ArticleId><ArticleId IdType="pmc">PMC7561673</ArticleId><ArticleId IdType="pubmed">33132986</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel B., Murphy R.E., Karanth S., Shiffaraw S., Peters R.M., Jr., Hohmann S.F., Greenberg R.S. Surge in Incidence and Coronavirus Disease 2019 Hospital Risk of Death, United States, September 2020 to March 2021. Open Forum Infect Dis. 2022;9:ofac424. doi: 10.1093/ofid/ofac424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac424</ArticleId><ArticleId IdType="pmc">PMC9550629</ArticleId><ArticleId IdType="pubmed">36225742</ArticleId></ArticleIdList></Reference><Reference><Citation>Delahoy M., Ujamaa D., Whitaker M., O’Halloran A., Anglin O., Burns E., Cummings C., Holstein R., Kambhampati A.K., Milucky J., et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents—COVID-NET, 14 States, March 1, 2020–August 14, 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1255–1260. doi: 10.15585/mmwr.mm7036e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7036e2</ArticleId><ArticleId IdType="pmc">PMC8437052</ArticleId><ArticleId IdType="pubmed">34499627</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor C. COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status—COVID-NET, 14 States, July 2021–January 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:466–473. doi: 10.15585/mmwr.mm7112e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7112e2</ArticleId><ArticleId IdType="pmc">PMC8956338</ArticleId><ArticleId IdType="pubmed">35324880</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers F.P., Pham H., Taylor C.A., Whitaker M., Patel K., Anglin O., Kambhampati A.K., Milucky J., Zell E., Moline H.L., et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern. Med. 2022;182:1071–1081. doi: 10.1001/jamainternmed.2022.4299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.4299</ArticleId><ArticleId IdType="pmc">PMC9459904</ArticleId><ArticleId IdType="pubmed">36074486</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sanidad M. Situación actual Coronavirus.  [(accessed on 24 January 2024)]; Available online:  https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual.htm.</Citation></Reference><Reference><Citation>Stefanelli P., Trentini F., Petrone D., Mammone A., Ambrosio L., Manica M., Guzzetta G., d’Andrea V., Marziano V., Zardini A., et al. Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. Euro Surveill. 2022;27:2200125. doi: 10.2807/1560-7917.ES.2022.27.45.2200125.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.45.2200125</ArticleId><ArticleId IdType="pmc">PMC9650705</ArticleId><ArticleId IdType="pubmed">36367013</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of the Further Spread and Potential Impact of the SARS-CoV-2 Omicron Variant of Concern in the EU/EEA, 19th Update. 2022.  [(accessed on 15 October 2023)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/covid-19-omicron-risk-assessment-further-emergence-and-potential-impact.</Citation></Reference><Reference><Citation>Markov P., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Soheili M., Khateri S., Moradpour F., Mohammadzedeh P., Zareie M., Mortazavi S.M.M., Manifar S., Kohan H.G., Moradi Y. The efficacy and effectiveness of COVID-19 vaccines around the world: A mini-review and meta-analysis. Ann. Clin. Microbiol. Antimicrob. 2023;22:42. doi: 10.1186/s12941-023-00594-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-023-00594-y</ArticleId><ArticleId IdType="pmc">PMC10198032</ArticleId><ArticleId IdType="pubmed">37208749</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder T., Koch J., Vygen-Bonnet S., Külper-Schiek W., Pilic A., Reda S., Scholz S., Wichmann O. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance. 2021;26:2100563. doi: 10.2807/1560-7917.ES.2021.26.28.2100563.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.28.2100563</ArticleId><ArticleId IdType="pmc">PMC8284046</ArticleId><ArticleId IdType="pubmed">34269175</ArticleId></ArticleIdList></Reference><Reference><Citation>Graña C., Ghosn L., Evrenoglou T., Jarde A., Minozzi S., Bergman H., Buckley B.S., Probyn K., Villanueva G., Henschke N., et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;12:CD015477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.R., Jiang Y.W., Li F.X., Liu D., Lin T.F., Zhao Z.Y., Wei C., Jin Q.Y., Li X.M., Jia Y.X., et al. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: A systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4:e236–e246. doi: 10.1016/S2666-5247(22)00390-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00390-1</ArticleId><ArticleId IdType="pmc">PMC9974155</ArticleId><ArticleId IdType="pubmed">36868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O., Barnsley G., Toor J., Hogan A., Winskill P., Ghani A. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng B., Gao L., Zhou Q., Yu K., Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02397-y</ArticleId><ArticleId IdType="pmc">PMC9126103</ArticleId><ArticleId IdType="pubmed">35606843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad, Consumo y Bienestar Social  Portal Estadistico. Area de Inteligencia de Gestion.  [(accessed on 6 July 2019)].  Available online:  https://pestadistico.inteligenciadegestion.mscbs.es/publicoSNS/comun/ArbolNodos.aspx?idNodo=23525.</Citation></Reference><Reference><Citation>Data on COVID-19 vaccination in the EU/EEA. 2023.  [(accessed on 15 October 2023)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea.</Citation></Reference><Reference><Citation>Garcia-Carretero R., Vazquez-Gomez O., Gil-Prieto R., Gil-de Miguel A. Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020–2021) BMC Infect. Dis. 2023;23:476. doi: 10.1186/s12879-023-08454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08454-y</ArticleId><ArticleId IdType="pmc">PMC10353154</ArticleId><ArticleId IdType="pubmed">37464303</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto de Salud Carlos III  Informe no 128 Situación de COVID-19 en España a 10 de mayo de 2022.pdf. 2022.  [(accessed on 9 June 2022)].  Available online:  https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/INFORMES%20COVID-19%202022/Informe%20n%C2%BA%20128%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2010%20de%20mayo%20de%202022.pdf.</Citation></Reference><Reference><Citation>Gobierno de España  Estrategia de vacunación COVID-19.  [(accessed on 12 September 2024)]; Available online:  https://www.vacunacovid.gob.es/</Citation></Reference><Reference><Citation>Rodriguez-Maroto G., Atienza-Diez I., Ares S., Manrubia S. Vaccination strategies in structured populations under partial immunity and reinfection. J. Phys. A Math. Theor. 2023;56:204003. doi: 10.1088/1751-8121/accda3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1751-8121/accda3</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vigil-Medina L., Barquero-Perez O., Ramos-Lopez J. Relevant Features in Nonalcoholic Steatohepatitis Determined Using Machine Learning for Feature Selection. Metab. Syndr. Relat. Disord. 2019;17:444–451. doi: 10.1089/met.2019.0052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2019.0052</ArticleId><ArticleId IdType="pubmed">31675274</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Barquero-Perez O., Mora-Jimenez I., Soguero-Ruiz C., Goya-Esteban R., Ramos-Lopez J. Identification of clinically relevant features in hypertensive patients using penalized regression: A case study of cardiovascular events. Med. Biol. Eng. Comput. 2019;57:2011–2026. doi: 10.1007/s11517-019-02007-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11517-019-02007-9</ArticleId><ArticleId IdType="pubmed">31346948</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vigil-Medina L., Barquero-Perez O., Mora-Jimenez I., Soguero-Ruiz C., Goya-Esteban R., Ramos-Lopez J. Logistic LASSO and Elastic Net to Characterize Vitamin D Deficiency in a Hypertensive Obese Population. Metab. Syndr. Relat. Disord. 2020;18:79–85. doi: 10.1089/met.2019.0104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2019.0104</ArticleId><ArticleId IdType="pubmed">31928513</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team  . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2020.  [(accessed on 12 September 2024)].  Available online:  https://www.r-project.org/</Citation></Reference><Reference><Citation>Farsalinos K., Poulas K., Vantarakis A., Leotsinidis M., Kouvelas D., Docea A.O., Kostoff R., Gerotziafas G.T., Antoniou M.N., Polosa R., et al. Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare. Toxicol. Rep. 2021;8:1–9. doi: 10.1016/j.toxrep.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxrep.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7713637</ArticleId><ArticleId IdType="pubmed">33294384</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors M., Graham B., Lane H., Fauci A. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann. Intern. Med. 2021;174:687–690. doi: 10.7326/M21-0111.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-0111</ArticleId><ArticleId IdType="pmc">PMC7839932</ArticleId><ArticleId IdType="pubmed">33460347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustin T., Harel N., Finkel U., Perchik S., Harari S., Tahor M., Caspi I., Levy R., Leshchinsky M., Ken Dror S., et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 2021;27:1379–1384. doi: 10.1038/s41591-021-01413-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01413-7</ArticleId><ArticleId IdType="pmc">PMC8363499</ArticleId><ArticleId IdType="pubmed">34127854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer-Babajew D., Finkin S., Viant C., Gaebler C., Hoffmann H.H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vazquez-Gomez O., Ordoñez-Garcia M., Garrido-Peño N., Gil-Prieto R., Gil-de Miguel A. Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020–2022) Viruses. 2023;15:1616. doi: 10.3390/v15071616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071616</ArticleId><ArticleId IdType="pmc">PMC10384448</ArticleId><ArticleId IdType="pubmed">37515302</ArticleId></ArticleIdList></Reference><Reference><Citation>Barandalla I., Alvarez C., Barreiro P., de Mendoza C., González-Crespo R., Soriano V. Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. Int. J. Infect. Dis. 2021;112:81–88. doi: 10.1016/j.ijid.2021.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.022</ArticleId><ArticleId IdType="pmc">PMC8442297</ArticleId><ArticleId IdType="pubmed">34536609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentís A., Kislaya I., Nicolay N., Meijerink H., Starrfelt J., Martínez-Baz I., Castilla J., Nielsen K.F., Hansen C.H., Emborg H.-D., et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Eurosurveillance. 2022;27:2200551. doi: 10.2807/1560-7917.ES.2022.27.30.2200551.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.30.2200551</ArticleId><ArticleId IdType="pmc">PMC9336167</ArticleId><ArticleId IdType="pubmed">35904059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyon F., Suman M., Fahim M., Ahmmed M. Time series analysis and predicting COVID-19 affected patients by ARIMA model using machine learning. J. Virol. Methods. 2022;301:114433. doi: 10.1016/j.jviromet.2021.114433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114433</ArticleId><ArticleId IdType="pmc">PMC8669956</ArticleId><ArticleId IdType="pubmed">34919977</ArticleId></ArticleIdList></Reference><Reference><Citation>Maleki M., Mahmoudi M., Wraith D., Pho K. Time series modelling to forecast the confirmed and recovered cases of COVID-19. Travel Med. Infect. Dis. 2020;37:101742. doi: 10.1016/j.tmaid.2020.101742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101742</ArticleId><ArticleId IdType="pubmed">33081974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kırbaş İ., Sözen A., Tuncer A., Kazancıoğlu F. Comparative analysis and forecasting of COVID-19 cases in various European countries with ARIMA, NARNN and LSTM approaches. Chaos Solitons Fractals. 2020;138:110015. doi: 10.1016/j.chaos.2020.110015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chaos.2020.110015</ArticleId><ArticleId IdType="pmc">PMC7293493</ArticleId><ArticleId IdType="pubmed">32565625</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabi K., Tahmid M., Rafi A., Kader M., Haider M. Forecasting COVID-19 cases: A comparative analysis between recurrent and convolutional neural networks. Results Phys. 2021;24:104137. doi: 10.1016/j.rinp.2021.104137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rinp.2021.104137</ArticleId><ArticleId IdType="pmc">PMC8054028</ArticleId><ArticleId IdType="pubmed">33898209</ArticleId></ArticleIdList></Reference><Reference><Citation>Makridakis S., Spiliotis E., Assimakopoulos V., Semenoglou A., Mulder G., Nikolopoulos K. Statistical, machine learning and deep learning forecasting methods: Comparisons and ways forward. J. Oper. Res. Soc. 2023;74:840–859. doi: 10.1080/01605682.2022.2118629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01605682.2022.2118629</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker C., Walker P.G., Alhaffar M., Hamlet A., Djaafara B.A., Ghani A., Ferguson N., Dahab M., Checchi F., Watson O.J. Under-reporting of deaths limits our understanding of true burden of COVID-19. BMJ. 2021;375:n2239. doi: 10.1136/bmj.n2239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2239</ArticleId><ArticleId IdType="pubmed">34642172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression Shrinkage and Selection via the Lasso. JOurnal R. Stat. Soc. Ser. B (Methodol.) 1996;58:267–288. doi: 10.1111/j.2517-6161.1996.tb02080.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1996.tb02080.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L. Random Forests. Mach. Learn. 2001;45:5–32. doi: 10.1023/A:1010933404324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010933404324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler D., Edwards T., Jr., Beard K., Cutler A., Hess K., Gibson J., Lawler J.J. Random forests for classification in ecology. Ecology. 2007;88:2783–2792. doi: 10.1890/07-0539.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1890/07-0539.1</ArticleId><ArticleId IdType="pubmed">18051647</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vazquez-Gomez O., Lopez-Lomba M., Gil-Prieto R., Gil-de Miguel A. Insulin Resistance and Metabolic Syndrome as Risk Factors for Hospitalization in Patients with COVID-19: Pilot Study on the Use of Machine Learning. Metab. Syndr. Relat. Disord. 2023;21:443–452. doi: 10.1089/met.2023.0083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2023.0083</ArticleId><ArticleId IdType="pubmed">37669018</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vigil-Medina L., Mora-Jimenez I., Soguero-Ruiz C., Barquero-Perez O., Ramos-Lopez J. Use of a K-nearest neighbors model to predict the development of type 2 diabetes within 2 years in an obese, hypertensive population. Med. Biol. Eng. Comput. 2020;58:991–1002. doi: 10.1007/s11517-020-02132-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11517-020-02132-w</ArticleId><ArticleId IdType="pubmed">32100174</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>